Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISRG's Cash to Debt is ranked higher than
96% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. ISRG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ISRG' s 10-Year Cash to Debt Range
Min: 12.85   Max: No Debt
Current: No Debt

Equity to Asset 0.87
ISRG's Equity to Asset is ranked higher than
92% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.52 vs. ISRG: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
ISRG' s 10-Year Equity to Asset Range
Min: 0.7   Max: 0.9
Current: 0.87

0.7
0.9
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
97% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISRG' s 10-Year Interest Coverage Range
Min: 232.79   Max: 9999.99
Current: No Debt

232.79
9999.99
F-Score: 6
Z-Score: 21.91
M-Score: -2.40
WACC vs ROIC
4.22%
22.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.13
ISRG's Operating margin (%) is ranked higher than
97% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -10.56 vs. ISRG: 28.13 )
Ranked among companies with meaningful Operating margin (%) only.
ISRG' s 10-Year Operating margin (%) Range
Min: -191.81   Max: 40.3
Current: 28.13

-191.81
40.3
Net-margin (%) 21.44
ISRG's Net-margin (%) is ranked higher than
95% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -12.96 vs. ISRG: 21.44 )
Ranked among companies with meaningful Net-margin (%) only.
ISRG' s 10-Year Net-margin (%) Range
Min: -180.68   Max: 41.41
Current: 21.44

-180.68
41.41
ROE (%) 14.26
ISRG's ROE (%) is ranked higher than
85% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -14.48 vs. ISRG: 14.26 )
Ranked among companies with meaningful ROE (%) only.
ISRG' s 10-Year ROE (%) Range
Min: -86.04   Max: 24.85
Current: 14.26

-86.04
24.85
ROA (%) 12.19
ISRG's ROA (%) is ranked higher than
92% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -7.12 vs. ISRG: 12.19 )
Ranked among companies with meaningful ROA (%) only.
ISRG' s 10-Year ROA (%) Range
Min: -58.81   Max: 22
Current: 12.19

-58.81
22
ROC (Joel Greenblatt) (%) 137.88
ISRG's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -26.51 vs. ISRG: 137.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISRG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1443.26   Max: 245.9
Current: 137.88

-1443.26
245.9
Revenue Growth (3Y)(%) 9.00
ISRG's Revenue Growth (3Y)(%) is ranked higher than
85% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 9.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISRG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 57.1
Current: 9

0
57.1
EBITDA Growth (3Y)(%) -3.80
ISRG's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: -3.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISRG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.7   Max: 321.3
Current: -3.8

-62.7
321.3
EPS Growth (3Y)(%) -3.40
ISRG's EPS Growth (3Y)(%) is ranked higher than
80% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: -3.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISRG' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.5   Max: 76.8
Current: -3.4

-61.5
76.8
» ISRG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ISRG Guru Trades in Q2 2014

Vanguard Health Care Fund 414,400 sh (New)
Manning & Napier Advisors, Inc 161,350 sh (New)
George Soros 45,100 sh (New)
Joel Greenblatt 15,023 sh (+76.72%)
Robert Olstein 17,000 sh (+41.67%)
Jeremy Grantham 67,006 sh (+28.04%)
RS Investment Management 268,929 sh (+18.23%)
Ray Dalio Sold Out
Frank Sands 1,939,418 sh (-11.53%)
Jim Simons 63,400 sh (-41.57%)
» More
Q3 2014

ISRG Guru Trades in Q3 2014

John Hussman 5,000 sh (New)
John Burbank 1,219 sh (New)
Ray Dalio 1,923 sh (New)
Steven Cohen 61,900 sh (New)
Dodge & Cox 500 sh (New)
Jeremy Grantham 170,743 sh (+154.82%)
Vanguard Health Care Fund 414,400 sh (unchged)
George Soros Sold Out
Frank Sands Sold Out
Manning & Napier Advisors, Inc 158,050 sh (-2.05%)
Robert Olstein 15,000 sh (-11.76%)
RS Investment Management 210,219 sh (-21.83%)
Jim Simons 45,070 sh (-28.91%)
Joel Greenblatt 10,420 sh (-30.64%)
» More
Q4 2014

ISRG Guru Trades in Q4 2014

Paul Tudor Jones 400 sh (New)
Ray Dalio 7,137 sh (+271.14%)
John Burbank 4,062 sh (+233.22%)
Jim Simons 74,500 sh (+65.30%)
Steven Cohen 66,200 sh (+6.95%)
Vanguard Health Care Fund 414,400 sh (unchged)
John Hussman 5,000 sh (unchged)
Dodge & Cox Sold Out
Manning & Napier Advisors, Inc 152,290 sh (-3.64%)
Jeremy Grantham 161,141 sh (-5.62%)
Robert Olstein 11,000 sh (-26.67%)
Joel Greenblatt 6,800 sh (-34.74%)
RS Investment Management 98,529 sh (-53.13%)
» More
Q1 2015

ISRG Guru Trades in Q1 2015

Jim Simons 228,270 sh (+206.40%)
John Hussman 10,000 sh (+100.00%)
John Burbank 4,938 sh (+21.57%)
Vanguard Health Care Fund 414,400 sh (unchged)
Robert Olstein 11,000 sh (unchged)
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
Joel Greenblatt 6,762 sh (-0.56%)
Jeremy Grantham 155,911 sh (-3.25%)
Manning & Napier Advisors, Inc 144,950 sh (-4.82%)
Steven Cohen 62,500 sh (-5.59%)
RS Investment Management 38,304 sh (-61.12%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Intuitive Surgical Inc

Baron Funds Comments on Intuitive Surgical - May 05, 2014

We sold out of the last of long-term holding Intuitive Surgical, Inc. (ISRG) Intuitive was one of the great investments in the Fund's history, but we let go of the last remnants of our position as the stock rebounded, and we felt uncertain about the device's utility in some of its new general surgery applications. Intuitive also has a $16 billion market cap on sale (it was $350 million on purchase!), and we need to be cognizant of market cap in our portfolio construction.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Nov 21, 2013

Intuitive Surgical, Inc. (ISRG), which sells the da Vinci robotic surgical systems, fell 25.7% in the quarter when results fell short of expectations as growth in procedures slowed and unit placements declined. Hospital admissions have been weak and negative publicity affected the amount of procedures performed. We reduced our position in the stock by half this year, but now believe the stock is oversold and too cheap.

From Ron Baron’s Baron Funds third quarter 2013 report.


Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Nov 06, 2013

Intuitive Surgical, Inc. (ISRG) sells the 'da Vinci' robotic surgical system. The company's recent results fell short of expectations because of a slowdown in domestic benign gynecological procedures using da Vinci devices. This, in turn, led to slower than expected overall procedure growth and systems sales; management lowered its full year 2013 guidance as a result. After recognizing significant profits, we trimmed our position in the stock earlier this year because of concerns about the impact that increased focus on cost containment in the healthcare system might have on the company's long- term growth prospects. We continue to own a small position in the Fund.

From Ron Baron's Baron Funds third quarter 2013 report.


Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Manning & Napier's Top 5 Second Quarter Stock Buys
Manning & Napier Advisers Inc., a New York investment management firm with $54.1 billion in assets under management, had a portfolio valued at $25.5 billion at June 30. Managers purchased 52 new positions in the second quarter, the top five largest of which are: Priceline Group Inc. (PCLN), Intuitive Surgical Inc. (ISRG), ProShares Short 20+ Year Treasury ETF (TBF), ARRIS Group Inc. (ARRS) and Republic Airways Holdings Inc. (RJET). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.40
ISRG's P/E(ttm) is ranked higher than
69% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 38.40 )
Ranked among companies with meaningful P/E(ttm) only.
ISRG' s 10-Year P/E(ttm) Range
Min: 17.79   Max: 207.43
Current: 38.4

17.79
207.43
Forward P/E 25.91
ISRG's Forward P/E is ranked higher than
67% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 25.91 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.20
ISRG's PE(NRI) is ranked higher than
75% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 39.20 )
Ranked among companies with meaningful PE(NRI) only.
ISRG' s 10-Year PE(NRI) Range
Min: 17.8   Max: 208.65
Current: 39.2

17.8
208.65
P/B 5.00
ISRG's P/B is ranked lower than
69% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. ISRG: 5.00 )
Ranked among companies with meaningful P/B only.
ISRG' s 10-Year P/B Range
Min: 2.07   Max: 15.72
Current: 5

2.07
15.72
P/S 8.25
ISRG's P/S is ranked lower than
96% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 8.25 )
Ranked among companies with meaningful P/S only.
ISRG' s 10-Year P/S Range
Min: 4.16   Max: 24.31
Current: 8.25

4.16
24.31
PFCF 35.80
ISRG's PFCF is ranked higher than
73% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 35.80 )
Ranked among companies with meaningful PFCF only.
ISRG' s 10-Year PFCF Range
Min: 18.4   Max: 506.71
Current: 35.8

18.4
506.71
POCF 29.67
ISRG's POCF is ranked higher than
72% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 29.67 )
Ranked among companies with meaningful POCF only.
ISRG' s 10-Year POCF Range
Min: 11.33   Max: 191.38
Current: 29.67

11.33
191.38
EV-to-EBIT 27.31
ISRG's EV-to-EBIT is ranked higher than
76% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 27.31 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s 10-Year EV-to-EBIT Range
Min: -164.8   Max: 244.8
Current: 27.31

-164.8
244.8
PEG 3.47
ISRG's PEG is ranked higher than
93% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 3.47 )
Ranked among companies with meaningful PEG only.
ISRG' s 10-Year PEG Range
Min: 0.17   Max: 7.15
Current: 3.47

0.17
7.15
Shiller P/E 38.20
ISRG's Shiller P/E is ranked higher than
74% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 38.20 )
Ranked among companies with meaningful Shiller P/E only.
ISRG' s 10-Year Shiller P/E Range
Min: 30.83   Max: 740.63
Current: 38.2

30.83
740.63
Current Ratio 4.29
ISRG's Current Ratio is ranked higher than
76% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. ISRG: 4.29 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s 10-Year Current Ratio Range
Min: 2.07   Max: 7.43
Current: 4.29

2.07
7.43
Quick Ratio 3.85
ISRG's Quick Ratio is ranked higher than
77% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ISRG: 3.85 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s 10-Year Quick Ratio Range
Min: 1.72   Max: 7.07
Current: 3.85

1.72
7.07
Days Inventory 92.78
ISRG's Days Inventory is ranked higher than
79% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 198.08 vs. ISRG: 92.78 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s 10-Year Days Inventory Range
Min: 52.29   Max: 122.83
Current: 92.78

52.29
122.83
Days Sales Outstanding 48.53
ISRG's Days Sales Outstanding is ranked higher than
85% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 96.55 vs. ISRG: 48.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s 10-Year Days Sales Outstanding Range
Min: 48.57   Max: 106.78
Current: 48.53

48.57
106.78

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.60
ISRG's Price/Net Cash is ranked higher than
75% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 21.60 )
Ranked among companies with meaningful Price/Net Cash only.
ISRG' s 10-Year Price/Net Cash Range
Min: 2.88   Max: 333.4
Current: 21.6

2.88
333.4
Price/Net Current Asset Value 15.60
ISRG's Price/Net Current Asset Value is ranked higher than
61% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 15.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISRG' s 10-Year Price/Net Current Asset Value Range
Min: 2.21   Max: 28.5
Current: 15.6

2.21
28.5
Price/Tangible Book 5.40
ISRG's Price/Tangible Book is ranked lower than
54% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. ISRG: 5.40 )
Ranked among companies with meaningful Price/Tangible Book only.
ISRG' s 10-Year Price/Tangible Book Range
Min: 3.5   Max: 16.35
Current: 5.4

3.5
16.35
Price/DCF (Projected) 1.60
ISRG's Price/DCF (Projected) is ranked higher than
86% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 1.60 )
Ranked among companies with meaningful Price/DCF (Projected) only.
ISRG' s 10-Year Price/DCF (Projected) Range
Min: 1.46   Max: 14.73
Current: 1.6

1.46
14.73
Price/Median PS Value 0.80
ISRG's Price/Median PS Value is ranked higher than
82% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 0.80 )
Ranked among companies with meaningful Price/Median PS Value only.
ISRG' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 2.09
Current: 0.8

0.31
2.09
Price/Peter Lynch Fair Value 6.40
ISRG's Price/Peter Lynch Fair Value is ranked higher than
86% of the 374 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 6.40 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ISRG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.81   Max: 6.68
Current: 6.4

0.81
6.68
Price/Graham Number 3.00
ISRG's Price/Graham Number is ranked higher than
71% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 3.00 )
Ranked among companies with meaningful Price/Graham Number only.
ISRG' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 7.88
Current: 3

1.76
7.88
Earnings Yield (Greenblatt) 3.70
ISRG's Earnings Yield (Greenblatt) is ranked higher than
76% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -2.60 vs. ISRG: 3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ISRG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 9.8
Current: 3.7

0.4
9.8
Forward Rate of Return (Yacktman) 9.08
ISRG's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ISRG: 9.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
ISRG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.1   Max: 141.9
Current: 9.08

-1.1
141.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:IUI1.Germany,
Intuitive Surgical Inc is a Delaware corporation founded in 1995. The Company designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories. A da Vinci Surgical System consists of a surgeon's console, a patient-side cart, and a high performance vision system. da Vinci Surgery utilizes computational, robotic and imaging technologies to enable improved patient outcomes compared to other surgical and non-surgical therapies. The Company has commercialized four generations of da Vinci Surgical System— the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. da Vinci Surgical Systems are comprised of the following components: Surgeon's Console. The da Vinci Surgical System allows surgeons to operate while comfortably seated at an ergonomic console viewing a 3-D image of the surgical field. Patient-Side Cart. The patient-side cart holds electromechanical arms that manipulate the instruments inside the patient. 3-D Vision System. Our vision system includes its InSite 3-D endoscope with two separate vision channels linked to two separate color monitors through high performance video cameras and specialized image processing hardware. da Vinci Skills Simulator. The Skills Simulator is a practice tool that gives a user the opportunity to practice his or her facility with the surgeon console controls. EndoWrist Instruments, the company manufactures a variety of instruments, most of which incorporate wrist joints for natural dexterity, with tips customized for various surgical procedures. EndoWrist instruments are offered in a variety of sizes, of which 5mm and 8mm diameter sizes are the most commonly sold. The Company provide its products through a direct sales organization in the U.S.; most of Western Europe excluding Spain, Portugal, Italy and Greece; Japan and Korea. The Company's products and operations are subject to extensive and rigorous regulation by the FDA, the State of California and countries or regions in which the company markets its products.
» More Articles for ISRG

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Google Inc, Bank of New York Mellon Corp, and Intuitive Surgical Inc. May 03 2015 
Google Set To Bring In A Difference In The World Of Surgery Mar 30 2015 
Weekly Insider Sells Highlight: FDO, MSFT, ISRG, INTC Feb 02 2015 
Compounding or Confounding: The Agony of the Sale Dec 20 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
Manning & Napier's Top 5 Second Quarter Stock Buys Jul 23 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows May 08 2014 
Baron Funds Comments on Intuitive Surgical May 05 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows May 01 2014 
5 Depressed Companies Ready for a Rebound - Worthy of a December Buy! Dec 13 2013 

More From Other Websites
Intuitive Surgical Reports New Employee Option Grants for May 2015 May 18 2015
Intuitive Surgical Reports New Employee Option Grants for May 2015 May 18 2015
Robotic Surgery Market– Global Analysis, Trends & Growth Prospects from Technavio May 18 2015
Coverage initiated on Intuitive Surgical by Piper Jaffray May 12 2015
Weekly CFO Sells Highlight: Google Inc, Bank of New York Mellon Corp, and Intuitive Surgical Inc. May 04 2015
5 Things You Missed in Intuitive Surgical's Report May 01 2015
INTUITIVE SURGICAL INC Financials Apr 28 2015
INTUITIVE SURGICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Apr 28 2015
10-Q for Intuitive Surgical, Inc. Apr 24 2015
INTUITIVE SURGICAL INC Files SEC form 10-Q, Quarterly Report Apr 22 2015
Intuitive Surgical: Shrinking Margins Trump Growing Procedures Apr 22 2015
Intuitive Surgical Q1 Earnings, Revenues Miss; Shares Fall - Analyst Blog Apr 22 2015
Intuitive Surgical (ISRG) Earnings Report: Q1 2015 Conference Call Transcript Apr 22 2015
Morning Movers: Chipotle Crumbles on Supply Woes; Boeing Bombs on Revenue Miss Apr 22 2015
Early movers: BA, KO, TMO, NLSN, AN & more Apr 22 2015
Amgen, Illumina Earnings Hot, Intuitive Surgical Not Apr 21 2015
After-hours buzz: Amgen, Yahoo, Chipotle & more Apr 21 2015
Intuitive Surgical Announces First Quarter Earnings Apr 21 2015
Intuitive Surgical Inc Earnings Call scheduled for 4:30 pm ET today Apr 21 2015
Intuitive Surgical misses Street 1Q forecasts Apr 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK